Ascendis Pharma (ASND) Tops Q1 EPS by 68c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR1.98), EUR0.68 better than the analyst estimate of (EUR2.66). Revenue for the quarter came in at EUR28.97 million versus the consensus estimate of EUR21.15 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c
• Performance Food Group (PFGC) Misses Q4 EPS by 1c ; Offers Guidance